<--- Back to Details
First PageDocument Content
Health economics / B-cell chronic lymphocytic leukemia / Lymphocytic leukemia / Lymphoma / Orphan drugs / Leukemia / Chlorambucil / End point of clinical trials / Rituximab / Medicine / Oncology / Health
Date: 2015-04-22 23:39:46
Health economics
B-cell chronic lymphocytic leukemia
Lymphocytic leukemia
Lymphoma
Orphan drugs
Leukemia
Chlorambucil
End point of clinical trials
Rituximab
Medicine
Oncology
Health

Add to Reading List

Source URL: www.pbs.gov.au

Download Document from Source Website

File Size: 216,60 KB

Share Document on Facebook

Similar Documents

Histopathology / End point of clinical trials / Response Evaluation Criteria in Solid Tumors / Vismodegib / Medicine / Basal-cell carcinoma / Carcinoma

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma (BCC): 24-month update of the pivotal ERIVANCE BCC study A Sekulic,1 MR Migden,2 AE Oro,3 L Dirix,4 K Lewis,5 JD Hainsworth,6

DocID: 1gamh - View Document

Non-small-cell lung carcinoma / Kaplan–Meier estimator / Squamous-cell carcinoma / End point of clinical trials / Neutropenia / Medicine / Oncology / Lung cancer

PDF Document

DocID: 1aW8t - View Document

Chemistry / Sulfones / Vismodegib / Basal-cell carcinoma / End point of clinical trials / Medicine / Oncology / Organochlorides

Long-Term Safety and Efficacy of Vismodegib in Patients With Advanced Basal Cell Carcinoma (aBCC): 18-Month Update of the Pivotal ERIVANCE BCC Study Aleksandar Sekulic,1 Michael R. Migden,2 Nicole Basset-Seguin,3 Claus G

DocID: 1axH7 - View Document

Organofluorides / Angiology / Growth factors / Tyrosine kinase inhibitors / Pyridines / Vascular endothelial growth factor / Sunitinib / End point of clinical trials / Sorafenib / Chemistry / Organic chemistry / Biology

New target: FGFR & c-MET Laurence Albiges Gustave Roussy Institute, Dana-Farber Cancer Institute New target : FGFR, c-MET

DocID: 19uI3 - View Document

Pyrimidines / Gastrointestinal cancer / Gastrointestinal stromal tumor / Imatinib / Chronic myelogenous leukemia / Dermatofibrosarcoma protuberans / End point of clinical trials / Leukemia / Medicine / Oncology / Piperazines

PUBLIC SUMMARY DOCUMENT Product: Imatinib, tablet, 100 mg and 400 mg (as mesylate), Glivec® Sponsor: Novartis Pharmaceuticals Australia Pty Ltd Date of PBAC Consideration: NovemberPurpose of Application

DocID: 197HX - View Document